Intraoral adenoid cystic carcinoma: The role of postoperative radiotherapy in local control
β Scribed by Jacqueline E. Der Van Waal; Gordon B. Snow; Abul B. M. F. Karim; Dr. Isaac Van Der Waal
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 247 KB
- Volume
- 11
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
β¦ Synopsis
Fourteen cases of adenoid cystic carcinoma (ACC) of the intraoral salivary glands with positive surgical margins have been reviewed in order to determine the role of postoperative radiotherapy in local control. Since local control was obtained in all patients, postoperative radiotherapy seems an adequate treatment to deal with the problem of positive surgical margins at the microscopic level, in cases of intraoral ACC, making additional surgical treatment redundant. HEAD & NECK 11 :497-499,
1989
Adenoid cystic carcinoma (ACC) of the salivary glands accounts for less than 1% of all head and neck malignancies and for approximately 10% of all salivary gland neoplasms.' It is the most common malignancy in the minor salivary glands.
ACC is a biologically aggressive tumor characterized by slow growth, insiduous infiltration From the Departments of Oral Pathology and Oral and Maxillofacial Surgery (Drs. J.E. van der Wal and I. van der Waal), Otolaryngology (Dr.
π SIMILAR VOLUMES
Background and Objectives: During the past few years, radiotherapy (RT) has been increasingly used in combination with surgery in the treatment of locally advanced laryngeal carcinomas to improve survival rates in patients with more extensive tumors. Methods: This is a retrospective study of a large
## BACKGROUND. The purpose of this study was to test the role of radiotherapy follow-
## Background: This study was conducted to investigate the influence of therapeutic parameters on local control (lc) in the sphincter-conserving treatment of t2-t3 anal carcinoma. ## Methods: From 1976 to 1993, 137 patients with anal carcinoma classified as t2 (85 patients) or t3 (52 patients) we